司、腾讯公益慈 善基金会等作为 企业代表发言。 在省委、省政府 的 高 位 推 动 下，"6·30"活动 聚爱助力"百千 万工程"，广东 省乡村振兴基金 会积极参与2025 年广东 省"6·30"助力乡 村振兴活动_南 方+_南方plus 7月2日，以"聚 焦 ' 百 千 万 工 程' ，巩固拓展 脱贫攻坚成果， 助力乡村全面振 兴"为主题的广 东 省 2025 年"6·30"助力乡 村振兴活动（以 下简称"6·30"活 动）仪式在广州 举行。由广东省 乡村振兴基金会 （以下简称"基 金会"）推荐参 与会见的爱心企 业共有9家，其 中基金会理事单 位广东长隆集团 有限公司、星河 湾 集 团 有 限 公 十 五 载 接 续 奋 斗、岁物丰成， 得到社会各界爱 心单位、爱心人 士的积极响应和 踊跃参与。今年 活动现场开展了 爱心企业、爱心 人士举牌认捐活 动 。 作 为"6·30"活动指 定省级捐款接收 单位之一 ，基金 会全力协助做好 各项工作，携手 广东长隆集团有 限公司、星河湾 集团有限公司、 腾讯公益慈善基 金会、侨鑫集团 有限公司、广东 省能源集团有限 公司，玖龙纸业 （控股）有限公 司、广东海大集 团 ...

Group 1 - The company has decided to terminate the control change plan and the A-share issuance plan after three years of planning, reflecting a proactive adjustment based on the current market environment and long-term development strategy [1] - The termination of the plans allows the management to focus on core business operations and strategic transformation, demonstrating a pragmatic attitude and strategic determination in response to market changes [1][3] - The company aims to concentrate resources on the high-growth potential medical device sector, having established a solid foundation in the medical device distribution field with a comprehensive supply chain network covering over 20 provinces and cities in China [2] Group 2 - The company has deepened strategic cooperation with top brands such as Siemens and Mindray Medical, laying a foundation for market expansion and service upgrades [2] - By actively divesting non-core assets and completing significant goodwill impairment, the company has effectively alleviated historical burdens, allowing for a focus on high-value areas [2] - The company achieved a revenue of 30.317 billion yuan in 2024, showcasing the resilience of its core business despite a challenging market environment [2] Group 3 - As a private enterprise, the company possesses natural advantages in decision-making efficiency, flexibility, and market sensitivity, which are reflected in its proactive adjustment of capital pathways [3] - The strategic focus on the medical device sector aligns with the industry's trend towards specialization, high value, and efficiency, providing the company with a broad space for future development [3] - The termination of the control change and capital increase plans marks a new phase in the company's strategic focus, laying a solid foundation for high-quality future development [3]

| | 证券代码：000078 | | | | 证券简称：海王生物 | | | | | 公告编号：2025-034 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | 深圳市海王生物工程股份有限公司 | | | | | | | | | | | | | | | | | 本公司及董事局全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 | | | | | | | | | | | | | 导性陈述或重大遗漏。 | | | | | | | | | | | | | | | | 特别提示： | | | | | | | | | | | | | | | | | | | 深圳市海王生物工程股份有限公司（以下简称"公司"）控股股东深圳海王集 | | | | | | | | | | | | | | | 团股份有限公司（以下简称"海王集团"）合计质押公司股份数量为1,214,318,878 | | | | | | | | | | | | | | | | 股， ...

中国经济网北京6月9日讯 海王生物（000078）（000078.SZ）6月7日发布关于终止控制权变更及向特定 对象发行股票事项的公告。近日，公司、海王集团及丝纺集团签署了《<关于深圳市海王生物工程股份 有限公司之合作协议书>解除协议》，丝纺集团与海王集团及其一致行动人张思民、张锋、王菲签署了 《<关于深圳市海王生物工程股份有限公司之股份转让协议>及<关于深圳市海王生物工程股份有限公司 之表决权放弃协议>解除协议》，公司本次控制权变更事项终止。 鉴于公司控制权变更事项终止，公司于2025年6月6日召开了2025年第三次独立董事专门会议、第九届董 事局第二十四次会议、第九届监事会第二十次会议，审议通过了终止向特定对象发行A股股票事项的相 关事项，同意终止向特定对象发行A股股票，并签署股份认购协议的解除协议。 海王生物2024年7月30日披露《2024年度向特定对象发行A股股票预案》称，本次向特定对象发行A股股 票的发行对象为丝纺集团及其控股股东广新集团。丝纺集团、广新集团拟以现金方式认购公司本次发行 的全部股票。 丝纺集团取得上市公司控制权后，按照拟发行股数计算，本次发行完成后，丝纺集团及其一致行动人持 有的上 ...

Core Viewpoint - The proposed change of control for Haiwang Bio has been officially terminated after over three years of planning, with the company deciding to halt the stock issuance to specific parties and the transfer of control [1][3][4]. Group 1: Control Change and Stock Issuance - Haiwang Bio announced the termination of its control change and stock issuance to specific parties, which was intended to be executed through stock transfer and voting rights relinquishment [1][3]. - The control change involved the transfer of 316 million unrestricted circulating shares from the controlling shareholder, Shenzhen Haiwang Group, to Guangdong Silk and Textile Group, representing 12% of the total shares [1][3]. - The termination was formalized through the signing of a termination agreement, with all parties confirming no breach of contract or other liabilities [3][4]. Group 2: Financial Performance - Haiwang Bio has reported consecutive losses over the past three years, with revenues of approximately 37.83 billion, 36.42 billion, and 30.32 billion yuan for 2022 to 2024, and corresponding net losses of about 1.03 billion, 1.69 billion, and 1.19 billion yuan [4]. - In the first quarter of this year, the company experienced a revenue decline of 8.81% year-on-year, totaling approximately 7.38 billion yuan, and a net profit drop of 44.38%, amounting to about 24 million yuan [5]. - The company's high debt ratio is concerning, with an asset-liability ratio of 89.76% reported at the end of the first quarter [5]. Group 3: Future Plans and Market Position - Despite the termination of the control change, Haiwang Bio plans to continue discussions with interested state-owned entities regarding equity cooperation to explore new development opportunities [4]. - The company has indicated that its business operations are proceeding normally and that the termination of the control change will not adversely affect its ongoing operations and stable development [4].

Core Viewpoint - The company has decided to terminate its plan for a specific issuance of A-shares for 2024 after discussions with strategic investors, indicating a strategic adjustment in its operations [1][2]. Group 1: Termination of A-share Issuance - The termination of the A-share issuance will not have a substantial impact on the company's normal operations or harm shareholder interests [1]. - The decision was made after friendly consultations with Shenzhen Haiwang Group Co., Ltd. and Guangdong Silk Textile Group Co., Ltd. [1]. Group 2: Business Strategy and Performance - The company has been focusing on restructuring its business, particularly in the medical device sector, while divesting non-core and underperforming assets to enhance operational efficiency [1][2]. - In 2024, the company achieved a revenue of 30.317 billion yuan, maintaining steady growth despite a complex market environment [1]. - The company has completed goodwill impairment provisions, laying a solid foundation for future development [1]. Group 3: Medical Device Business - The company has established a comprehensive supply chain network covering over 20 provinces and cities in China, maintaining long-term stable partnerships with international brands like Siemens and Mindray Medical [2]. - Future plans include expanding the scale of its medical device agency business and deepening strategic cooperation with high-quality domestic and international suppliers [2]. Group 4: Financial Management and Outlook - As of the end of 2024, the company's goodwill was valued at approximately 379 million yuan, allowing it to focus on high-value-added business areas [2]. - The company has successfully completed equity transfers of several subsidiaries, optimizing its asset structure and supporting its transformation [2]. - Although facing short-term financial pressures, the effective release of goodwill risks and the strengthening of core businesses are expected to improve the company's operational status and create sustainable value for investors [2].